Drug Shortage Report for NUCALA
| Report ID | 130613 |
| Drug Identification Number | 02492989 |
| Brand name | NUCALA |
| Common or Proper name | Mepolizumab Injection |
| Company Name | GLAXOSMITHKLINE INC |
| Market Status | MARKETED |
| Active Ingredient(s) | MEPOLIZUMAB |
| Strength(s) | 100MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | PRE-FILLED AUTOINJECTOR x1 / AUTOINJECTEUR PRÉ-REMPLI x1 |
| ATC code | R03DX |
| ATC description | OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-12-18 |
| Estimated end date | 2021-02-01 |
| Actual end date | 2021-01-20 |
| Shortage status | Resolved |
| Updated date | 2021-01-21 |
| Company comments | |
| Health Canada comments | |
| Company contact information | 1-800-387-7374 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.